These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15954334)

  • 1. [Allergic conjunctival disorders].
    Ebihara N
    Nihon Rinsho; 2005 May; 63 Suppl 5():107-13. PubMed ID: 15954334
    [No Abstract]   [Full Text] [Related]  

  • 2. A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: effects of new topical ocular drugs.
    Yanni JM; Sharif NA; Gamache DA; Miller ST; Weimer LK; Spellman JM
    Acta Ophthalmol Scand Suppl; 1999; (228):33-7. PubMed ID: 10337430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo.
    Galatowicz G; Ajayi Y; Stern ME; Calder VL
    Clin Exp Allergy; 2007 Nov; 37(11):1648-56. PubMed ID: 17877767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell.
    Leonardi A; Quintieri L
    Expert Opin Pharmacother; 2010 Apr; 11(6):969-81. PubMed ID: 20307221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.
    Kida T; Fujii A; Sakai O; Iemura M; Atsumi I; Wada T; Sakaki H
    Exp Eye Res; 2010 Jul; 91(1):85-91. PubMed ID: 20412793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Allergic conjunctivitis from cellular involvement to medical practice].
    Nicodin A
    Oftalmologia; 2007; 51(2):96-9. PubMed ID: 17937044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with galectin-1 eye drops regulates mast cell degranulation and attenuates the severity of conjunctivitis.
    Mello-Bosnic C; Gimenes AD; Oliani SM; Gil CD
    Eur J Pharmacol; 2018 Aug; 833():124-130. PubMed ID: 29859836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Opatanol].
    Johansen S
    Ugeskr Laeger; 2003 Jul; 165(30):2957. PubMed ID: 12926197
    [No Abstract]   [Full Text] [Related]  

  • 9. Eosinophil as a cellular target of the ocular anti-allergic action of mapracorat, a novel selective glucocorticoid receptor agonist.
    Baiula M; Spartà A; Bedini A; Carbonari G; Bucolo C; Ward KW; Zhang JZ; Govoni P; Spampinato S
    Mol Vis; 2011; 17():3208-23. PubMed ID: 22194647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ocular injuries due to allergic mechanism].
    Nenciu A; Stefan C
    Oftalmologia; 2002; 53(2):9-13. PubMed ID: 12474434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Contact dermatitis].
    Yokozeki H
    Nihon Rinsho; 2005 May; 63 Suppl 5():131-5. PubMed ID: 15954338
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effects of emedastine eyedrops on acute seasonal allergic conjunctivitis in children].
    Endre L
    Orv Hetil; 2003 Apr; 144(14):665-7. PubMed ID: 12795028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Alomide eyedrops in the treatment of allergic conjunctivitis and keratoconjunctivitis].
    Maĭchuk IuF; Khaitova KN; Grishakova MB
    Vestn Oftalmol; 1998; 114(4):43-4. PubMed ID: 9771090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research.
    Rosenwasser LJ; O'Brien T; Weyne J
    Curr Med Res Opin; 2005 Sep; 21(9):1377-87. PubMed ID: 16197656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Allergic conjunctivitis].
    Ishizaki M
    Ryoikibetsu Shokogun Shirizu; 2000; (31):539-42. PubMed ID: 11269157
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
    Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS
    Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New aspects in drug therapy of ocular allergies].
    Maĭchuk IuF
    Vestn Oftalmol; 2000; 116(5):10-4. PubMed ID: 11221368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Participation of CD11b and F4/80 molecules in the conjunctival eosinophilia of experimental allergic conjunctivitis.
    Fukushima A; Ishida W; Ojima A; Kajisako M; Sumi T; Yamada J; Tsuru E; Miyazaki J; Tominaga A; Yagita H
    Int Arch Allergy Immunol; 2010; 151(2):129-36. PubMed ID: 19752566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking mast cell-mediated type I hypersensitivity in experimental allergic conjunctivitis by monocyte chemoattractant protein-1/CCR2.
    Tominaga T; Miyazaki D; Sasaki S; Mihara S; Komatsu N; Yakura K; Inoue Y
    Invest Ophthalmol Vis Sci; 2009 Nov; 50(11):5181-8. PubMed ID: 19553621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.